Fujian Cosunter Pharmaceutical Co Ltd (300436) - Total Assets
Based on the latest financial reports, Fujian Cosunter Pharmaceutical Co Ltd (300436) holds total assets worth CN¥1.41 Billion CNY (≈ $206.91 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Fujian Cosunter Pharmaceutical Co Ltd - Total Assets Trend (2011–2025)
This chart illustrates how Fujian Cosunter Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see market value of Fujian Cosunter Pharmaceutical Co Ltd for the company's overall valuation and market capitalisation.
Fujian Cosunter Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Fujian Cosunter Pharmaceutical Co Ltd's total assets of CN¥1.41 Billion consist of 36.5% current assets and 63.5% non-current assets. Review Fujian Cosunter Pharmaceutical Co Ltd (300436) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.3% |
| Accounts Receivable | CN¥76.25 Million | 5.4% |
| Inventory | CN¥124.85 Million | 8.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥188.97 Million | 13.5% |
| Goodwill | CN¥58.97 Million | 4.2% |
Asset Composition Trend (2011–2025)
This chart illustrates how Fujian Cosunter Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 300436 stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fujian Cosunter Pharmaceutical Co Ltd's current assets represent 36.5% of total assets in 2025, a decrease from 47.1% in 2011.
- Cash Position: Cash and equivalents constituted 15.3% of total assets in 2025, down from 35.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 9.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 13.5% of total assets.
Fujian Cosunter Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Fujian Cosunter Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Dr. Reddy's Laboratories Limited
F:RDDA
|
Germany | €562.90 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Apeloa Pharmaceutical Co Ltd
SHE:000739
|
China | CN¥12.25 Billion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥22.22 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.70 Billion |
Fujian Cosunter Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.02 | 0.69 | 2.31 |
| Quick Ratio | 0.77 | 0.47 | 2.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥8.63 Million | CN¥-170.03 Million | CN¥381.95 Million |
Fujian Cosunter Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Fujian Cosunter Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 63.68 |
| Latest Market Cap to Assets Ratio | 1.51 |
| Asset Growth Rate (YoY) | -2.7% |
| Total Assets | CN¥1.40 Billion |
| Market Capitalization | $2.12 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Fujian Cosunter Pharmaceutical Co Ltd's assets above their book value (1.51x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Fujian Cosunter Pharmaceutical Co Ltd's assets decreased by 2.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Fujian Cosunter Pharmaceutical Co Ltd (2011–2025)
The table below shows the annual total assets of Fujian Cosunter Pharmaceutical Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.40 Billion ≈ $204.93 Million |
-2.66% |
| 2024-12-31 | CN¥1.44 Billion ≈ $210.54 Million |
-10.88% |
| 2023-12-31 | CN¥1.61 Billion ≈ $236.25 Million |
+8.00% |
| 2022-12-31 | CN¥1.49 Billion ≈ $218.74 Million |
+3.32% |
| 2021-12-31 | CN¥1.45 Billion ≈ $211.71 Million |
+43.80% |
| 2020-12-31 | CN¥1.01 Billion ≈ $147.22 Million |
+12.25% |
| 2019-12-31 | CN¥896.25 Million ≈ $131.15 Million |
+4.86% |
| 2018-12-31 | CN¥854.68 Million ≈ $125.07 Million |
+16.05% |
| 2017-12-31 | CN¥736.47 Million ≈ $107.77 Million |
+5.11% |
| 2016-12-31 | CN¥700.67 Million ≈ $102.53 Million |
+16.64% |
| 2015-12-31 | CN¥600.70 Million ≈ $87.90 Million |
+168.03% |
| 2014-12-31 | CN¥224.11 Million ≈ $32.79 Million |
+13.46% |
| 2013-12-31 | CN¥197.53 Million ≈ $28.90 Million |
+32.21% |
| 2012-12-31 | CN¥149.41 Million ≈ $21.86 Million |
+36.71% |
| 2011-12-31 | CN¥109.29 Million ≈ $15.99 Million |
-- |
About Fujian Cosunter Pharmaceutical Co Ltd
Fujian Cosunter Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. The company offers drugs for anti-HBV, liver diseases, hepatobiliary disease drugs, metabolism and digestive system, respiratory, cardiovascular, men's health, and other fields. It also provides technical services such as drug development, including the deve… Read more